No, company got this data starting in 2019, and Linda Liau, with other top scientists, wrote a whole scientific paper on how to get this data when it needs to be gotten in retrospect.
Since they have known for quite some time that long-term survivors were IDH wild-type and mesenchymal, as discussed off-handedly in multiple LL presentations on YouTube, it is clear they knew this was coming and had been addressing it for some time.
But it’s a biomarker, not something that can’t be determined after the fact, it was driven by the larger community’s greater understanding of the science, so it was not done by NWBO, and it shows that DCVax’ hypothesized, but widely understood to be the case, mechanism works exactly as expected, more mutations, more efficacy.
It only helps, in my view. It puts the icing on the cake. The science is confirmed by the broader community’s independently derived science conclusions. How could that possibly hurt an efficacious drug. It only hurts a bogus drug trying to get over.
Market Data 
Markets 
AI
